A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Blood

Volumn 120, Issue 9, 2012, Pages 1801-1809

  Jakubowiak, Andrzej J ^a,b   Dytfeld, Dominik ^b,c   Griffith, Kent A ^b   Lebovic, Daniel ^b   Vesole, David H ^d   Jagannath, Sundar ^e   Al Zoubi, Ammar ^b   Anderson, Tara ^b   Nordgren, Brian ^b   Detweiler Short, Kristen ^b   Stockerl Goldstein, Keith ^f   Ahmed, Asra ^b   Jobkar, Terri ^b   Durecki, Diane E ^b   McDonnell, Kathryn ^a   Mietzel, Melissa ^b   Couriel, Daniel ^b   Kaminski, Mark ^b   Vij, Ravi ^f  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d Hackensack UMC   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARFILZOMIB; CIPROFLOXACIN; CLOPIDOGREL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PROTON PUMP INHIBITOR; VALACICLOVIR; WARFARIN;

ADULT; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASE; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MALE; METHEMOGLOBINEMIA; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PNEUMOCYSTIS CARINII; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VEIN THROMBOSIS; VOMITING;

EID: 84865333050     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-422683     Document Type: Article

References (41)

1. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stemcell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-4629.
2. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116(26):5838-5841.
3. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431-436.
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617.
5. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123- 2132.
6. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-1571.
7. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomidedexamethasone (BLD). Hematology. 2010;15(2):70-73.
8. Roussel M, Avet-Loiseau H, Moreau P, et al. Frontline therapy with bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 phase II study [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):3041. Abstract 624.
9. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
10. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085.
11. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduceddose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752-5758.
12. Anderson KC, Alsina M, Bensinger W, et al. National Comprehensive Cancer Network. Multiple myeloma. J Natl Compr Canc Netw. 2011;9(10):1146-1183.
13. Jakubowiak AJ, Kendall T, Al-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol. 2009;27(30):5015-5022.
14. Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010;116(19):3743-3750.
15. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progressionfree and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025-3031.
16. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol. 2009;27(34):5720-5726.
17. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775-5782.
18. Moreau P, Attal M, Pegourie B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011;117(11):3041-3044.
19. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progressionfree survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92(10):1399-1406.
20. Dytfeld D, Griffith KA, Friedman J, et al. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein - based model: extended follow-up of a phase II trial. Leuk Lymphoma. 2011;52(7):1271-1280.
21. Arastu-Kapur S, Anderl JL, Kraus M, et al. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734-2743.
22. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383-6391.
23. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281-3290.
24. Siegel D, Kaufman J, Wang M, et al. A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R MM) [abstract]. Haematologica. 2011;96(Suppl 2):126. Abstract 0302.
25. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119(24):5661-5670.
26. Singhal S, Siegel DS, Martin T, et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21). Abstract 1876.
27. Siegel D, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma [published online ahead of print July 25, 2012]. Blood. doi:10.1182/blood-2012-05-425934.
28. Wang M, Bensinger W, Martin T, et al. Interim results from PX-171-006, a phase (ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM) [ASCO abstract]. J Clin Oncol. 2011;29(15s). Abstract 8025.
29. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
30. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
31. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
32. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177-1182.
33. Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56mg/m2 expansion cohort of PX-171-007 [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21). Abstract 2930.
34. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services; 2006. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed June 7, 2012.
35. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123.
36. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365-1372.
37. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
38. Jakubowiak AJ, Dytfeld D, Jagannath S, et al. Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I/II MMRC Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21). Abstract 862.
39. Roussel M, Robillard N, Moreau P, et al. Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the IFM 2008 Phase II VRD Intensive Program [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21). Abstract 1872.
40. International Myeloma Working Group. Consensus guidelines for the management of deep venous thrombosis (DVT) in multiple myeloma. Program and abstracts of the13th International Myeloma Workshop, May 3-6, 2011, Paris, France. http://www.myeloma-paris2011.com/files/files/ConsensusPanel1DVTTheFinal. pdf. Accessed March 5, 2012.
41. Oakervee H, Popat R, Cavenagh JD. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk Lymphoma. 2007;48(10):1910-1921.